In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
- 13 November 2010
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (17) , 2753-2755
- https://doi.org/10.1097/qad.0b013e32833f9e36
Abstract
In this study of nine clinical isolates obtained from integrase inhibitor-naïve HIV-2-infected patients, the median EC50 value for the new integrase inhibitor S/GSK1349572 was 0.8 nM (range 0.2–1.4), and is similar to HIV-1 reference strains. We found a seven-, 13- and 18-fold increase in EC50 values to S/GSK1349572 for the HIV-2 double (T97A + Y143C; G140S + Q148R) and triple (G140T + Q148R + N155H) mutants, respectively, obtained from two raltegravir-experienced patients.Keywords
This publication has 10 references indexed in Scilit:
- Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance GenotypesJournal of Virology, 2009
- Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacityJournal of Clinical Virology, 2009
- Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patientsJournal of Antimicrobial Chemotherapy, 2009
- HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitroJournal of Antimicrobial Chemotherapy, 2008
- Raltegravir treatment response in an HIV-2 infected patient: a case reportAIDS, 2008
- In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor ResistanceAntiviral Therapy, 2007
- Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load AssayJournal of Clinical Microbiology, 2005
- Susceptibility of HIV-2, Siv and Shiv to Various Anti-HIV-1 Compounds: Implications for Treatment and Postexposure ProphylaxisAntiviral Therapy, 2004
- Locations of Anti-AIDS Drug Binding Sites and Resistance Mutations in the Three-dimensional Structure of HIV-1 Reverse TranscriptaseJournal of Molecular Biology, 1994